BioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call Transcript

BioStem Technologies, Inc. (OTCPK:BSEM) commenced its Q2 2025 earnings conference call on August 14, 2025, to discuss preliminary and unaudited financial results. The company explicitly stated that these results are subject to change pending the completion of a financial statement audit, which is contingent upon the resolution of an ongoing SEC review related to its planned NASDAQ uplisting. This underscores the provisional nature of the reported figures and highlights the regulatory considerations impacting the company's market trajectory.

Analysis

BioStem Technologies (BSEM) has introduced significant uncertainty into its Q2 2025 financial reporting by stating that the results are preliminary, unaudited, and subject to change. The finalization of these figures is directly contingent upon the completion of a financial statement audit, which itself is predicated on the resolution of an ongoing SEC review concerning the company's planned uplisting to the NASDAQ exchange. This regulatory hurdle overshadows any operational performance discussed, as the lack of audited financials prevents a reliable fundamental assessment. The cautious tone of the call underscores that the company's immediate future, including its ability to access a major exchange and provide definitive financial statements, is dependent on a regulatory process with an undefined timeline and outcome.

Key Decisions for Investors

• Investors should recognize that BSEM's near-term valuation is heavily dependent on the outcome of the ongoing SEC review, making regulatory news the primary catalyst to monitor over operational results.
• It is prudent to treat the preliminary Q2 2025 financial results with extreme caution, as they are unaudited and could be materially revised following the completion of the audit.
• Consider holding existing positions or delaying new investments until the company provides audited financials and a definitive update on the status of its NASDAQ uplisting.